Clinical Effect of Labetalol combined with Magnesium Sulfate in the Treatment of Preeclampsia
Objective To explore the clinical efficacy of using labetalol combined with magnesium sulfate in the treatment of preeclampsia(PE)patients.Methods Sixty PE patients who received treatment at Yellow River Sanmenxia Hospital from January 2020 to December 2023 were selected and randomly divided into control group(n=30)and study group(n=30)using a random number table method.The control group received magnesium sulfate treatment,while the study group received a combination of labetalol and magnesium sulfate treatment.The clinical efficacy,blood pressure,heart rate,urinary protein,placental hemodynamic parameters,coagulation function indicators,and maternal and infant adverse events were compared between two groups.Results The effective rate of treatment in the study group(96.67%)was higher than that in the control group(73.33%),and the difference was statistically significant(P＜0.05).After treatment,the blood pressure,heart rate(HR),and 24-hour urine protein levels in both groups were lower than those before treatment,and the study group was lower than the control group,with statistically significant differences(P＜0.05).After treatment,the placental hemodynamic parameters of the two groups were lower than those before treatment,and the study group was lower than the control group,with a statistically significant difference(P＜0.05).After treatment,the prothrombin time(PT)and activated partial thromboplastin time(APTT)of the two groups were longer than those before treatment,and the D-dimer(D-D)was lower than that before treatment.In addition,the PT and APTT of the study group were longer than those of the control group,and the D-D was higher than that of the control group,with statistical significance(P＜0.05).The incidence of maternal and infant adverse events in the study group(6.67%)was lower than that in the control group(30.00%),and the difference was statistically significant(P＜0.05).Conclusion The use of labetalol combined with magnesium sulfate in the treatment of PE patients can promote clinical efficacy,reduce blood pressure,HR,24-hour urine protein,improve placental hemodynamics and coagulation function,and reduce the occurrence of maternal and infant adverse events.
国家科技期刊平台
NSTL
万方数据
